Preclinical safety and toxicokinetic evaluation of TJ0113, a first-in-class mitophagy inducer for Parkinson's disease.

Mitochondrial dysfunction is a key driver of neurodegeneration, highlighting mitophagy as a tractable therapeutic axis. Yet the clinical translation of mitophagy-targeting agents requires robust, GLP-compliant nonclinical safety data to support and de-risk human trials in line with international guidelines. TJ0113, a first-in-class small-molecule inducer of mitophagy, has shown disease-modifying activity in preclinical models and is being evaluated in a registered, randomized, double-blind, placebo-controlled Phase II trial in Parkinson's disease (NCT06596005). We conducted a comprehensive safety assessment of TJ0113 in Sprague-Dawley rats and Beagle dogs under GLP. Single-dose studies (up to 1500 mg/kg, oral) and repeat-dose studies (rats: 15, 30, 100 mg/kg/day for 26 weeks; dogs: 6, 20, 60 mg/kg/day for 39 weeks) evaluated systemic toxicity, toxicokinetics (TK), safety pharmacology endpoints (including ECG), and a standard genotoxicity battery (Ames, chromosomal aberration, micronucleus) consistent with ICH S2(R1). No treatment-related mortality or target-organ toxicity occurred. A modest increase in relative kidney organ coefficient in rats was observed but without biochemical or histopathological correlates and was considered non-adverse. Clinical pathology, ECG, and dog urinalysis remained within physiological limits; all genotoxicity tests were negative. TK showed rapid absorption with linear, dose-proportional exposure and no accumulation at the end of dosing. The NOAELs were 100 mg/kg/day in rats (26 weeks) and 60 mg/kg/day in dogs (39 weeks). These data establish a favorable nonclinical safety profile for TJ0113 and provide GLP evidence supporting further clinical development of this selective mitophagy-targeting agent.